Robinson Smith Wealth Advisors LLC Purchases 65 Shares of Amgen Inc. (NASDAQ:AMGN)

Robinson Smith Wealth Advisors LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 805 shares of the medical research company’s stock after acquiring an additional 65 shares during the quarter. Robinson Smith Wealth Advisors LLC’s holdings in Amgen were worth $210,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Centricity Wealth Management LLC purchased a new stake in Amgen during the 4th quarter worth about $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at about $29,000. Synergy Investment Management LLC purchased a new stake in shares of Amgen in the 4th quarter valued at about $34,000. Atala Financial Inc purchased a new stake in shares of Amgen in the 4th quarter valued at about $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the 4th quarter valued at about $36,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. UBS Group reaffirmed a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Truist Financial lowered their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Redburn Partners decreased their price objective on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $314.04.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares of the company’s stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last quarter. 0.69% of the stock is owned by company insiders.

Amgen Price Performance

Shares of AMGN stock opened at $313.71 on Friday. The firm has a market cap of $168.53 billion, a P/E ratio of 41.55, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The business’s 50 day moving average price is $291.82 and its 200-day moving average price is $299.33. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.